Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 9/20 | 0.61 |
| ▸ | FAAH | O00519 | 2/20 | 0.51 |
| ▸ | ABHD6 | Q9BV23 | 2/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27276172 | 1.00 | MGLL (0.61) | MGLLFAAHABHD6CYP2D6PLA2G7 | |
| SCHEMBL31071511 | 1.00 | MGLL (0.61) | MGLLFAAHABHD6CYP2D6PLA2G7 | |
| SCHEMBL29616461 | 0.89 | MGLL (0.65) | MGLL | |
| SCHEMBL22462769 | 0.89 | MGLL (0.65) | MGLL | |
| SCHEMBL24095482 | 0.88 | MGLL (0.75) | MGLL | |
| SCHEMBL24095479 | 0.84 | MGLL (0.61) | MGLL | |
| SCHEMBL21723274 | 0.84 | MGLL (0.63) | MGLL | |
| SCHEMBL21730744 | 0.84 | MGLL (0.63) | MGLL | |
| SCHEMBL21723273 | 0.84 | MGLL (0.63) | MGLL | |
| SCHEMBL21730857 | 0.80 | MGLL (0.75) | MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11802133-B2 | Heterocyclic compounds as monoacylglycerol lipase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2023-10-31 | — | — | US | disclosed |
| US-20230050901-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2023-02-16 | — | — | US | disclosed |
| US-20210277020-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2021-09-09 | — | — | US | disclosed |
| US-20200308190-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2020-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210277020-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | MGLL, PNLIP, LPL | MGLL 1/4885FAAH 48/4885ABHD6 19/4885 |
| US-20200308190-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | LIPC, MGLL, LPL | MGLL 2/4885FAAH 61/4885ABHD6 20/4885 |
| US-11802133-B2 | Heterocyclic compounds as monoacylglycerol lipase inhibitors | LIPC, LPL, MGLL | MGLL 3/4885FAAH 60/4885ABHD6 26/4885 |
| US-20230050901-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | LIPC, LPL, MGLL | MGLL 3/4885FAAH 60/4885ABHD6 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.